Showing 4781-4790 of 10098 results for "".
- Biologic Therapy in Psoriasis: Secukinumab and Ustekinumab Lead in Retentionhttps://practicaldermatology.com/news/biologic-therapy-in-psoriasis-secukinumab-and-ustekinumab-lead-in-retention/2471042/Switching patterns of biologics in psoriasis treatment revealed influences of gender and psoriatic arthritis (PsA), according to new research. The retrospective study from the nationwide digital prescription database of Greece has shed light on biologic treatment trends for psoriasis betwe
- Gene Expression Patterns Linked to Psoriasis Severity and Treatment Responsehttps://practicaldermatology.com/news/gene-expression-patterns-linked-to-psoriasis-severity-and-treatment-response/2470916/Gene expression abnormalities not only reflect the severity of psoriatic lesions but also predict treatment response, according to a recent study published in JID Innovations. Researchers on the study analyzed gene expression profiles in psoriatic skin using Gene Set Variation Ana
- Study: Dual-Action Topical Treatment Reduces Lesion Counts in Adult Acne Patientshttps://practicaldermatology.com/news/study-dual-action-topical-treatment-reduces-lesion-counts-adult-acne-patients/2470855/Results from a recent pilot study suggested that a combination therapy of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel with clascoterone 1% cream was effective in reducing lesions in adult acne patients. Researchers for the study enrolled 20 adult participants with
- Melasma Clinical Trials Show Advancements in Inclusive Representationhttps://practicaldermatology.com/news/melasma-clinical-trials-show-advancements-inclusive-representation/2468760/A new analysis of melasma clinical trials indicates progress toward inclusivity, with broad gender, racial, and Fitzpatrick skin type (FST) representation. Researchers publishing in the Journal of Drugs in Dermatology analyzed melasma clinical trials listed on ClinicalTrials.gov,
- Study Highlights Gaps in Fitzpatrick Skin Type Determinationhttps://practicaldermatology.com/news/study-highlights-gaps-fitzpatrick-skin-type-determination/2468709/New research published in The Journal of Clinical and Aesthetic Dermatology evaluated concordance between self-assessed and provider-determined Fitzpatrick skin types (FSTs). Study researchers conducted the analysis of 472 patients attending a dermatology practice and included dat
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- Study: TPC2 Ion Channel Key Driver of Melanoma Progressionhttps://practicaldermatology.com/news/study-tpc2-ion-channel-key-driver-melanoma-progression/2468665/New research has succeeded in identifying a critical regulator of melanoma progression. The research, published by a group from Ludwig-Maximilians-Universität München in Nature Communications, highlights how TPC2 influences intracellular trafficking pathways that drive melanoma c
- Study: Botanical Gummies Show Promise for Thinning Hairhttps://practicaldermatology.com/news/study-botanical-gummies-show-promise-thinning-hair/2468582/A recent 6-month study found that a daily gummy supplement with B vitamins, zinc, and botanicals improved hair density, strength, and perceived hair quality in women with thinning hair. Researchers for the double-blind, placebo-controlled trial included 65 healthy female participants aged
- Starton Secures New Patent for Transdermal Lenalidomide Deliveryhttps://practicaldermatology.com/news/starton-secures-new-patent-transdermal-lenalidomide-delivery/2468506/Starton Therapeutics announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its STAR-LLD transdermal drug delivery patent application, providing potential extended patent protection through 2040. According to a press release, the development broad
- Verrica To Share Phase 2 Results for VP-315 in BCC Treatment at Fall Clinicalhttps://practicaldermatology.com/news/verrica-share-phase-2-results-vp-315-bcc-treatment-fall-clinical/2468470/Verrica Pharmaceuticals announced today that two abstracts featuring positive topline results from their phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC) will be presented at the 2024 Fall Clinical Dermatology Conference. The presentations will focus on safety, tole